Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer

Se Hoon Park, Caroline J. Breitbach, Jeeyun Lee, Joon Oh Park, Ho Yeong Lim, Won Ki Kang, Anne Moon, Jae Hee Mun, Erica M. Sommermann, Liliana Maruri Avidal, Rick Patt, Adina Pelusio, James Burke, Tae Ho Hwang, David Kirn, Young Suk Park

Research output: Contribution to journalArticle

67 Scopus citations

Abstract

Fifteen patients with treatment-refractory colorectal cancer were enrolled on a phase 1b study of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia designed to selectively replicate in cancer cells. Pexa-Vec was administered intravenously every 14 days, at dose levels of 1 × 10 6, 1 × 10 7, or 3 × 10 7 plaque-forming units (pfu)/kg. The primary endpoint was to determine the maximum tolerated dose. Secondary endpoints were pharmacokinetics and pharmacodynamics as well as antitumor activity. Patients were heavily pretreated (mean 4.5 lines of therapy). All patients received at least two Pexa-Vec doses (median = 4; range = 2-4). No dose-limiting toxicities were reported, and the maximum tolerated dose was not reached. The most common adverse events were grade 1/2 flu-like symptoms, generally lasting <24 hours. During the first and last cycles, genome pharmacokinetics were unchanged. Infectious pfu could be detected in plasma up to 2 hours after cycle 1 and up to 30 minutes after cycle 4 (when antivaccinia antibody titers are known to have peaked). Ten patients (67%) had radiographically stable disease. Given the acceptable safety profile of multiple intravenous Pexa-Vec infusions in patients with treatment-refractory colorectal cancer, further trials evaluating efficacy of intravenous Pexa-Vec, as monotherapy or in combination with chemotherapeutic agents, is warranted in this patient population.

Original languageEnglish
Pages (from-to)1532-1540
Number of pages9
JournalMolecular Therapy
Volume23
Issue number9
DOIs
StatePublished - 3 Sep 2015

Fingerprint Dive into the research topics of 'Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer'. Together they form a unique fingerprint.

  • Cite this

    Park, S. H., Breitbach, C. J., Lee, J., Park, J. O., Lim, H. Y., Kang, W. K., Moon, A., Mun, J. H., Sommermann, E. M., Maruri Avidal, L., Patt, R., Pelusio, A., Burke, J., Hwang, T. H., Kirn, D., & Park, Y. S. (2015). Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer. Molecular Therapy, 23(9), 1532-1540. https://doi.org/10.1038/mt.2015.109